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A  human  hookworm  vaccine  is under  development  and  in  clinical  trials  in Africa  and  the  Americas.  The
vaccine  contains  the  Na-APR-1  and  Na-GST-1  antigens.  It elicits  neutralizing  antibodies  that  interfere
with  establishment  of the adult  hookworm  in  the  gut  and  the  ability  of  the  parasite  to feed on  blood.  The
vaccine  target  product  proﬁle  is focused  on  the  immunization  of  children  to  prevent  hookworm  infection
and  anemia  caused  by Necator  americanus.  It is  intended  for use in  low-  and  middle-income  countries
where  hookworm  is highly  endemic  and  responsible  for  at least  three  million  disability-adjusted  lifeeglected tropical disease
years.  So  far,  the human  hookworm  vaccine  is being  developed  in  the  non-proﬁt  sector  through  the
Sabin  Vaccine  Institute  Product  Development  Partnership  (PDP),  in collaboration  with  the  HOOKVAC
consortium  of  European  and  African  partners.  We  envision  the  vaccine  to  be  incorporated  into  health
systems  as  part  of an  elimination  strategy  for hookworm  infection  and other  neglected  tropical  diseases,
and  as  a means  to reduce  global  poverty  and address  the  Sustainable  Development  Goals.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd. This  is  an  open  access  article  under  the  CCHuman hookworm infection is a neglected tropical disease
aused predominantly by the nematode parasite Necator ameri-
anus [1]. Recent estimates indicate that approximately 439 million
eople are infected with hookworm worldwide, with the majority
f cases found in the developing regions of South Asia (140 million
ases), Sub-Saharan Africa (118 million), Southeast Asia (77 mil-
ion), East Asia (64.5 million), and the Latin American and Caribbean
egion (30 million) [2,3]. In these areas, hookworm disease is a
ajor cause of iron-deﬁciency anemia, a consequence of the adult
ookworm’s ability to extract blood from the intestinal mucosa and
ubmucosa [4].
The Global Burden of Disease Study 2010 (GBD 2010) esti-
ated that hookworm is responsible for a loss of 3.2 million
isability adjusted life years (DALYs), making it one of the leading
eglected tropical diseases (along with schistosomiasis and leish-
aniasis) in terms of disease burden [2] and a leading cause of
nemia in large parts of Africa and Oceania [3,4] (Fig. 1). Hookworm
nfection occurs when the larval stages penetrate the skin of a
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human host. The primary adverse effect of infection, anemia, dis-
proportionately occurs in children and pregnant women  with lower
iron reserves compared to other populations [5,6]. Hookworm is
hyperendemic among some pediatric populations in sub-Saharan
Africa where in countries such as Sierra Leone or Togo one-third
of the population under the age of 20 is infected [7]. Children with
chronic hookworm infection experience anemia and cognitive and
developmental delays with resultant reductions in school perfor-
mance, attendance and future wage earnings [8,9]. Approximately
7 million pregnant women  in sub-Saharan Africa – almost one third
of annual pregnancies in Africa – are also infected, making hook-
worm disease one of the most common complications of pregnancy
in that part of the world [5]. Moreover, many of these individuals –
both children and pregnant women  – are co-infected with malaria,
thereby exacerbating anemia and its sequelae [10].
The primary approach to hookworm control is mass drug
administration with the anthelminthics albendazole (400 mg)  or
mebendazole (500 mg). However, a single dose of mebendazole,
administered once per year, has yielded low cure rates, particu-
larly with repeated use [11–13]. One comprehensive meta-analysis
showed no impact of mebendazole treatment on improving anemia
in hookworm-affected communities [6]. Similarly, for albendazole,
given as a single dose, once per year, drug failure has been reported,
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Fig. 1. Distribution of human hookworm infection.
(Reproduced with permission from Hotez et al. [42]).
Table 1
Development status of current vaccine candidates (POC = proof of concept trial).
Candidate name/identiﬁer Preclinical Phase I Phase II POC Phase III
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Na-GST-1 and Na-APR-1 Co-administered
hough less often [14]. Moreover, children can re-acquire hook-
orm several months after treatment, particularly in geographic
ocations with signiﬁcant infectivity or attack rates [15,16]. These
bservations may  explain a recent ﬁnding from GBD 2013 study
hat overall global hookworm prevalence has remained essentially
nchanged over the last 20 years, while the prevalence of other
eglected tropical diseases such as lymphatic ﬁlariasis, ascariasis,
nd trachoma has decreased by 25–33% over the same time period
17]. There is, therefore, a need for new technologies to achieve
etter control of hookworm infection, particularly if the world is
o meet the proposed targets set by the London Declaration for
eglected tropical diseases and the follow-up World Health Assem-
ly resolution 66.12 [18]. A safe and effective anti-hookworm
accine, as a complement to conventional chemotherapy, may
rovide a cost-effective means of reaching this goal [19] (Table 1).
. Biological feasibility for vaccine development
As hookworm infection does not typically confer immunity,
here is so far no natural immunological correlate of protection
n which to base a program for vaccine development. Hook-
orms have developed mechanisms to evade the host immune
ystem, enabling them to persist in their host for years. Even with
hemotherapy, reinfection is the rule. Furthermore, the prevalence
nd intensity of infection increases with age, adding more evidence
hat hookworm fails to elicit robust acquired immunity [20]. Proof
f concept was obtained by the relative success of a commercial
og vaccine that consisted of irradiated larvae. The vaccine was
eveloped for dogs during the 1960s and ’70s. Before its discon-
inuation, though, passive antibody transfer studies showed that
era from vaccinated dogs protected non-vaccinated dogs from
ookworm challenge [21]. However, clinical trials of hookworm
ecombinant larval antigens have revealed this approach to be
nfeasible because of a high prevalence of IgE antibodies toX
X
X
larval macromolecules such as Na-ASP-2 among some hookworm
endemic populations [22].
Proteins, especially enzymes, required for adult hookworm
blood-feeding may  hold promise as an alternative strategy for
hookworm vaccine development [23,24] (Fig. 2). This approach
was used successfully for a veterinary vaccine against the blood-
feeding trichostrongyle, Haemonchus contortus that infects sheep
and cattle [25]. The enzymes required for hemoglobin diges-
tion and heme detoxiﬁcation in hookworms have been identiﬁed,
cloned, expressed and shown to elicit protective antibodies [23,24].
Unlike the larval stage antigens there is no evidence that these
enzymes induce IgE antibodies. In the case of N. americanus, sev-
eral enzymes have been identiﬁed and developed into recombinant
immunogens, including aspartic protease-hemoglobinase, Na-APR-
1  (a critical enzyme for hemoglobin digestion) and glutathione
S-transferase-1 (Na-GST-1) (a unique form of the enzyme used
for parasite heme detoxiﬁcation) [23,24]. Both have demonstrated
efﬁcacy in immunization/challenge studies in dogs. The Na-APR-
1 vaccine elicited a neutralizing antibody and cellular response in
dogs. After challenge of the animals, it also lowered the hookworm
burden and the fecal egg counts in vaccinated dogs, compared to
control animals [26].
2. General approaches to vaccine development for low and
middle income country markets
The antigen selection strategy for a human hookworm vac-
cine is based on several key criteria: (1) preclinical efﬁcacy, (2)
absence of pre-vaccination antigen-speciﬁc IgE among endemic
populations, (3) ability to scale up protein manufacture, (4) iden-
tiﬁed mechanisms of protection [24]. We  have identiﬁed two  key
antigens in blood feeding, Na-APR-1 and Na-GST-1, which are the
leading candidates for clinical development. The eventual goal is
to license a vaccine that contains either or both of the recombi-
nant forms of these immunogens in formulation with an aluminum
P.J. Hotez et al. / Vaccine 34 (2016) 3001–3005 3003
Fig. 2. Enzymes required for parasite blood feeding. Adult worms in the gut ingest blood, and parasite hemolysins drill pores into the erythrocytes, releasing hemoglobin into
the  parasite gut lumen (step 1). Hemoglobin is digested by the hierarchical and ordered cascade of hemoglobinases (APR-1, an aspartic protease, CP-3, a cysteine protease, and
MEP-1, a metalloproteinase) lining the brush border membrane of the parasite gut (step 2). The globin peptides and free amino acids that are released following hemoglobin
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Reproduced with permission from [24] Hotez et al., Nature Reviews Microbiology).
ydroxide adjuvant (Alhydrogel®). Clinical trials are also evaluating
hether an additional adjuvant is required to achieve acceptable
mmunogenicity. These adjuvants are synthetic Toll-like recep-
or (TLR) agonists, such as, glucopyranosyl lipid A (GLA) and CpG
ligodeoxynucleotide.
One of the cited reasons for the canine vaccine’s commercial fail-
re was that it did not provide sterilizing immunity, even though
his would not be a requirement for a human hookworm vaccine to
eliver a clinical beneﬁt. This is because the pathology of hookworm
nfections corresponds mainly with intestinal blood loss, which is
roportional to worm burden. The more important goal of a suc-
essful vaccine, then, is reduce the burden of infection and thereby
educe the loss of blood to a subclinical level. Thus, among the pro-
osed features of the vaccine’s target product proﬁle (TPP) is an
fﬁcacy of at least 80% not in preventing infection entirely, but in
reventing moderate and heavy infections caused by N. americanus
nd the resulting intestinal blood loss and anemia. Additionally, the
PP outlines a vaccine intended for at risk children under the age
f 10, stable between 2 ◦C and 8 ◦C and administered at no more
han two doses by intramuscular injection concurrently with other
hildhood vaccines [23].
. Technical and regulatory assessment
The two primary human hookworm vaccine candidates, Na-
ST-1 and Na-APR-1, have already completed or are currently
n Phase 1 ﬁrst-in-humans clinical trials in Brazil and in the US
27–32]. A co-administration trial with both vaccines is under-
ay in Gabon [29]. In order to quickly obtain regulatory approval
t is conceivable that the vaccine could ﬁrst be registered in
n endemic country, followed by WHO  prequaliﬁcation, or that
pproval is sought under article 58 of the European Medicines
gency (EMA). Of course, registration through the US Food and
rug Administration (FDA) remains as the conventional option.
he latter two pathways are complicated by the ﬁnding that hook-
orm infection is not endemic to the US or Europe except in smallree heme is detoxiﬁed by the action of glutathione S-transferase (GST-1) (step 4).
ins and interrupt blood feeding are shown.
focal areas. However, review by the EMA  or FDA is recognized
as high-level assurance of product quality and safety, and could
facilitate approval by national regulatory authorities in hookworm
disease-endemic countries. In order to evaluate the vaccine, clinical
endpoints, as well as parasitological endpoints (fecal egg counts,
corresponding to worm number, as well as fecal blood loss) are
being taken into consideration. In addition, it is conceivable that the
humoral immune response mounted against the vaccine antigen
candidates might serve as a correlate of protection.
4. Status of vaccine R&D activities
The preclinical downselection criteria that lead to the clinical
development of Na-GST-1 and Na-APR-1 have been reviewed else-
where [23,24]. In essence, these two  immunogens were the most
efﬁcacious in reducing hookworm burden and blood loss following
challenge of hamsters with N. americanus or dogs with A. caninum.
Both candidates are now in full-scale cGMP production and in phase
1 clinical trials. Na-GST-1 is being expressed in the yeast Pichia
pastoris [33,34] while Na-APR-1 is being produced in the Nicotiana
tobacco plant [35]. Each molecule is undergoing separate phase 1
testing as an alum formulation. Additionally, Na-GST-1, plus alum,
is being evaluated either with an aqueous formulation of the TLR
4 agonist, GLA, or the TLR-9 agonist, CpG deoxyoligonucleotide.
Na-APR-1 plus alum is being evaluated with GLA.
In addition, to phase 1 clinical testing, the Sabin PDP is also
developing a hookworm larval challenge model in human volun-
teers vaccinated with one or both antigens [30]. Early results to
determine feasibility of developing the challenge model in human
volunteers will be available in 2016. The Sabin PDP has a parallel
discovery program for new antigens screened from recently com-
pleted hookworm genome project [36]. Additionally, a large part of
the human hookworm vaccine development efforts are advancing
under HOOKVAC, a European Commission-supported Framework
Program 7 (FP7) project. Other members include the Amster-
dam Medical Center, Q Biologicals, Universität Tübingen, CERMEL
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Centre de Recherches Médicales de Lambaréné), Pharmidex,
eiden University, Baylor College of Medicine-Texas Children’s Hos-
ital, and George Washington University. The major objectives
f HOOKVAC are to: (1) establish safety and immunogenicity of
accine candidates in endemic populations, (2) improve manufac-
uring processes, (3) provide clinical proof-of-concept data through
esting in Gabon, and (4) ensure accessibility of the vaccine in
ndemic areas.
. Likelihood for ﬁnancing
As described previously, vaccine discovery and design
pproaches are mostly focused on subunit approaches for
elivering potentially protective targets. The bulk of these devel-
pment efforts is being supported through academic centers
nd product development partnerships. According to G-Finder,
rom 2007–2013, approximately $45 million were invested in
ookworm vaccine R&D [37] by donors from around the world,
ncluding: The Bill & Melinda Gates Foundation, European Commis-
ion, Dutch Ministry of Foreign Affairs, the Government of Brazil,
he National Institutes of Allergy and Infectious Diseases of the US
ational Institutes of Health (NIH) and Texas Children’s Hospital.
ngoing discovery is being supported by the Michelson Medical
esearch Foundation. Overall, however, a recent analysis has deter-
ined that on the basis of DALYs, hookworm currently ranks among
he most underfunded neglected tropical diseases [38]. Endemic
ountry demand will be critical to obtaining public sector support
o allow further development of these candidates, as well as build
upport for GAVI’s inclusion in a future vaccine portfolio, which
ow prioritizes vaccines that prevent under ﬁve-child mortality.
Still, availability of an afﬁcacious and inexpensive vaccine would
ecome a key technology in the prevention of hookworm anemia
39]. Moreover, additional new studies showing that hookworm
nfection accounts for a signiﬁcant percentage of the world’s iron
eﬁciency anemia [4], and further new estimates by GBD 2013 indi-
ating that iron-deﬁciency anemia is responsible for 183,400 deaths
nnually [40] should elevate the global urgency for advancing a
accine.
A human hookworm vaccine is seen not only as a crucial tool
n the path to eliminating the disease, but also as a means to to
educe poverty, particularly in developing economies. Hookworm
nfection has been identiﬁed as a major cause of poverty in low- and
iddle-income countries and because of hookworm’s potential for
dditive or synergistic effects on other co-infections of overlapping
eographic distributions, thus improving the overall public health
conomic development in endemic economies, making it a true
nti-poverty vaccine [41].
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